Laboratorios Farmaceuticos Rovi 관리
관리 기준 확인 3/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Juan Lopez-Belmonte Encina
최고 경영자
€1.3m
총 보상
| CEO 급여 비율 | 55.2% |
| CEO 임기 | 17.8yrs |
| CEO 소유권 | n/a |
| 경영진 평균 재임 기간 | 데이터 없음 |
| 이사회 평균 재임 기간 | 5.5yrs |
최근 관리 업데이트
Recent updates
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 10
With Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) It Looks Like You'll Get What You Pay For
Oct 21Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Aug 29Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Jul 15We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet
Jun 17Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price
May 08These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Apr 17Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?
Feb 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Dec 21Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?
Nov 03Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Aug 26Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate
Jul 14Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
May 26Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?
May 05Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate
Apr 11Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
Feb 22An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued
Dec 10These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely
Nov 04Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?
Sep 15Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Aug 28Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Jun 15I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease
Feb 13Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Jan 02A Look At The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
Dec 12Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Nov 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Sep 24Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Jun 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Apr 06Investors Who Bought Laboratorios Farmaceuticos Rovi (BME:ROVI) Shares Five Years Ago Are Now Up 205%
Mar 15If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late
Feb 16
Are Strong Financial Prospects The Force That Is Driving The Momentum In Laboratorios Farmaceuticos Rovi, S.A.'s BME:ROVI) Stock?
Jan 26These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Jan 04Announcing: Laboratorios Farmaceuticos Rovi (BME:ROVI) Stock Increased An Energizing 169% In The Last Five Years
Dec 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Growing Earnings But Are They A Good Guide?
Nov 26CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | €165m |
| Jun 30 2024 | n/a | n/a | €148m |
| Mar 31 2024 | n/a | n/a | €138m |
| Dec 31 2023 | €1m | €743k | €170m |
| Sep 30 2023 | n/a | n/a | €197m |
| Jun 30 2023 | n/a | n/a | €186m |
| Mar 31 2023 | n/a | n/a | €194m |
| Dec 31 2022 | €1m | €728k | €200m |
| Sep 30 2022 | n/a | n/a | €176m |
| Jun 30 2022 | n/a | n/a | €183m |
| Mar 31 2022 | n/a | n/a | €182m |
| Dec 31 2021 | €2m | €327k | €153m |
| Sep 30 2021 | n/a | n/a | €113m |
| Jun 30 2021 | n/a | n/a | €82m |
| Mar 31 2021 | n/a | n/a | €71m |
| Dec 31 2020 | €561k | €330k | €61m |
| Sep 30 2020 | n/a | n/a | €55m |
| Jun 30 2020 | n/a | n/a | €53m |
| Mar 31 2020 | n/a | n/a | €46m |
| Dec 31 2019 | €541k | €320k | €39m |
| Sep 30 2019 | n/a | n/a | €33m |
| Jun 30 2019 | n/a | n/a | €27m |
| Mar 31 2019 | n/a | n/a | €18m |
| Dec 31 2018 | €908k | €312k | €18m |
| Sep 30 2018 | n/a | n/a | €16m |
| Jun 30 2018 | n/a | n/a | €9m |
| Mar 31 2018 | n/a | n/a | €18m |
| Dec 31 2017 | €524k | €303k | €17m |
보상 대 시장: Juan 의 총 보상 ($USD 1.40M )은 Spanish 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 1.54M ).
보상과 수익: Juan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Juan Lopez-Belmonte Encina
17.8yrs
테뉴어
€1,346,000
보상
Mr. Juan Lopez-Belmonte Encina has been Chief Executive Officer of Laboratorios Farmaceuticos ROVI, S.A. since October 2007 and served as its President from October 2020 to October 2022. He has been with L...
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman & CEO | 17.3yrs | €1.35m | 데이터 없음 | |
| Second Deputy Chairman & GM of Commercial and Development | 17.3yrs | €552.00k | 데이터 없음 | |
| First Deputy Chairman | 17.3yrs | €554.00k | 데이터 없음 | |
| Independent Director | 5.5yrs | €80.00k | 데이터 없음 | |
| Independent Director | 4.9yrs | €80.00k | 데이터 없음 | |
| Director | 2.5yrs | €80.00k | 데이터 없음 | |
| Independent Director | 1.9yrs | €80.00k | 데이터 없음 |
5.5yrs
평균 재임 기간
경험이 풍부한 이사회: ROVI 의 이사회는 경험(평균 재직 기간 5.5 년)으로 간주됩니다.